Investigating the feasibility and acceptability of the TeleRehabilitation of balance clinical and economic Decision Support System (TeleRehaB DSS) in adults at risk of falls: study protocol for a multicentre clinical trial.

Publication date: Jun 25, 2026

Falls are a significant concern for older adults, particularly those with neurological, vestibular, cognitive and post-viral conditions, due to dizziness and imbalance. Conventional balance rehabilitation programmes, though effective, face challenges in adherence and accessibility. The TeleRehabilitation Decision Support System (TeleRehaB DSS) uses artificial intelligence (AI) and motion tracking to provide individualised multisensory balance rehabilitation (MBR) remotely. This trial aims to evaluate the acceptability, feasibility, safety and preliminary efficacy of a home-based TeleRehaB DSS among community-dwelling older adults at risk of falls due to stroke, mild cognitive impairment (MCI), long COVID and vestibular dysfunction. This multicentre, assessor-blinded randomised controlled trial will recruit 460 community-dwelling adults aged 40-80 years with stroke, MCI, vestibular dysfunction or long covid across five sites in the UK, Europe and Southeast Asia. Participants will be randomised to a 9-week remotely supervised home exercise programme using either TeleRehaB DSS (high-tech or low-tech MBR with exergames and cognitive training) or standard care (OTAGO home exercise programme or Meniere’s Dizziness booklet). Primary outcomes include feasibility, acceptability and safety, alongside clinical measures of balance and health-related quality of life (Functional Gait Assessment, EuroQol five-dimensional descriptive system instrument). Secondary outcomes assess balance, cognition, physical activity, dizziness, psychological well-being, fatigue and confidence. Usability, user experience and digital health literacy will also be evaluated. Anonymised data will undergo quality checks and be analysed using descriptive and exploratory statistics, mixed-effects models, cost-effectiveness analysis (incremental cost-effectiveness ratio) and thematic analysis of qualitative interviews, adjusting for site and relevant confounders. This study has received institutional ethical approvals in the UK, Germany, Greece and Thailand and from Madeira, Portugal. Findings from this study will be submitted for peer-reviewed publications. NCT06534164.

Open Access PDF

Concepts Keywords
Dizziness Artificial Intelligence
Germany Augmented Reality
Nct06534164 Brain Injuries
Thailand Clinical Trial
Viral Neurology
Telemedicine

Semantics

Type Source Name
drug DRUGBANK Isoxaflutole
disease MESH DSS
disease MESH dizziness
disease MESH face
disease MESH stroke
disease MESH mild cognitive impairment
disease MESH long COVID
disease MESH fatigue
drug DRUGBANK Indoleacetic acid
disease MESH COVID 19
disease MESH muscle weakness
disease MESH multiple sclerosis
disease MESH cerebellar disease
disease MESH vestibular neuritis
disease MESH labyrinthitis
disease MESH hypertension
disease MESH Parkinson’s disease
disease MESH aphasia
disease MESH injury
disease MESH migraines
drug DRUGBANK Etoperidone
disease MESH Anxiety
disease MESH ered
disease MESH plan
disease MESH emergency
drug DRUGBANK BK-MDA
disease MESH pain
drug DRUGBANK Methionine
disease MESH hemiplegia
drug DRUGBANK Aspartame
disease MESH PDs
pathway REACTOME Translation
disease MESH Lord
disease MESH Hearing Disorders
disease MESH Dis
disease MESH Neurologic Disorders
disease MESH wrist fractures
disease MESH pmc
disease MESH stenosis
disease MESH low back pain
pathway KEGG Parkinson disease
drug DRUGBANK Abacavir
disease MESH Chronic Pain
drug DRUGBANK Coenzyme M
disease MESH fac
disease MESH BPPV
disease MESH ICD
disease MESH Brain Injuries

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *